Long-read sequencing, enabling comprehensive coverage of TCR beta chain.Unlike other technologies, the Oncomine TCR Beta-LR Assay offers: To optimize the manufacture and function of therapeutic or engineered T cells.To identify variable gene polymorphisms implicated in autoimmune disease or immune-mediated adverse events.To characterize diversity and monitor features of T lymphocytes in blood and infiltrated tumors.Why are immunologists and immuno-oncologists interested in T cell repertoire sequencing research? Streamlined and user-friendly informatics solution with multi-sample analysis functionality.Compatibility with a variety of research sample types including fresh-frozen tissue, whole blood, and sorted cells.Flexible input requirements ranging from 10 ng to 1 µg.Efficient workflow with 48 hr sample-to-results time.Unbiased output generated from Ion AmpliSeq technology.Detection of clones over a wide dynamic range.Long-read RNA sequencing (up to 400 bp amplicon length) comprehensively covering TCR beta chain.Note: Information about data analysis using Ion Reporter Software v5.6 can be found in the User Guide below.īenefits of the Oncomine TCR Beta-LR Assay include: The use of RNA template allows sequencing of productive and relevant variable (V), diversity (D), and joining (J) rearrangements-improving the identification of rare clones. The identification of rare and abundant clones can be achieved with a flexible RNA input amount of 10 ng (minimum) and up to 1 µg. It enables key applications such as predictive or prognostic biomarker discovery, T cell characterization, and identification of variable gene polymorphisms. The assay is designed to efficiently capture all three complementarity determining regions of the TCR beta chain (CDR1, CDR2, CDR3) with high accuracy. Ion AmpliSeq libraries can be generated from research samples such as RNA extracted from whole blood, fresh-frozen tissue, or FACS-sorted cells. The assay kit provides a single pool of multiplex PCR primers, library reagents, and sample barcodes. This assay utilizes a newly developed long-read sequencing technology on the Ion GeneStudio S5 next-generation sequencing systems. Let us know how this access is important for you.The Oncomine TCR Beta-LR Assay is designed to measure T cell diversity and clonal expansion by sequencing T cell receptor beta chain rearrangements. Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Moreover, our findings suggest that betaAPP may not be a major physiological substrate of BACE. These data demonstrate that Abeta production is limited in polarized cells by differential targeting of BACE and its substrate betaAPP. Consistent with this finding, substantial amounts of Abeta can be produced apically upon missorting of betaAPP to the apical surface. In addition, no alpha-secretase activity was observed on the apical side whereas gamma-secretase activity is observed on the basolateral and the apical side. Therefore, substantial amounts of BACE are targeted away from betaAPP to a non-amyloidogenic compartment, a cellular mechanism that limits Abeta generation. The remaining basolaterally sorted BACE competes with the highly polarized basolateral alpha-secretase activity. Consistent with the usage of similar mechanisms for polarized sorting, BACE was also found to be targeted to axons of hippocampal neurons. The majority of BACE is sorted to the apical surface of MDCK cells where very little beta-amyloid precursor protein (betaAPP) is observed, because betaAPP undergoes basolateral sorting. We have now studied polarized sorting of beta-secretase (BACE) in Madin-Darby canine kidney (MDCK) cells. This implicates polarized sorting mechanisms in the production and accumulation of amyloid beta-peptide (Abeta). Polarized cells such as neurons and endothelial cells appear to be involved in two invariant pathological features of Alzheimer's disease pathology, namely the formation of senile plaques and cerebral amyloid angiopathy.
0 Comments
Leave a Reply. |